Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies
Status:
Unknown status
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with
thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients
with hematological undergone allogenic bone marrow transplantation and CMV positive.
The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the
infection complications.